Most material SEC filings — October 27, 2026

On October 26, 2026, Valion Bio closed two financing tranches: (1) 3i, LP purchased 50 Series B Preferred Shares for $50,000 with warrants to purchase 1,539 common shares at $1.0092/share; (2) multiple purchasers (including 3i, LP) purchased 4,717.73 Series C Preferred Shares for aggregate $4,717,717.61 ($3.2M via cash true-up credits, $1.5M cash) with warrants to purchase 2,524,343 common shares at $1.0092/share. 3i, LP has already purchased $13.637M of the $75M total Series C commitment and holds a $16.25M Senior Secured Convertible Note. Company must list on Nasdaq Capital Market and file registration statements within 30-60 days.

Ares Capital Corporation agreed to acquire MidCap Financial Investment Corporation in a two-step merger dated October 26, 2026. MidCap shareholders will receive $1.21 cash per share plus Parent Common Stock via an exchange ratio (exact ratio not specified in merger agreement text). MidCap has ~82.4M shares outstanding as of October 23, 2026; Parent has ~722.2M shares outstanding as of October 22, 2026. Transaction requires MidCap stockholder approval and regulatory clearances under HSR and antitrust laws.

Aclaris announced positive Phase 1b proof-of-concept results for ATI-052 (anti-TSLP/IL-4Rα bispecific) in atopic dermatitis (14 patients, 3:1 randomization) and asthma (16 patients, 3:1 randomization). In severe AD: 58% absolute EASI reduction (ATI-052) vs. 13% (placebo); 78% placebo-adjusted EASI-50; 38% absolute itch improvement. In asthma: 59% FeNO reduction and +350 mL FEV1 improvement at day 15 (in FEV1 ≥80% subgroup). No Grade 3/4 adverse events; no conjunctivitis. Company will prioritize Phase 2b in eosinophilic esophagitis (EoE), initiating early 2027, with potential additional indications announced later.

Imunon, Inc. (IMNN, market cap ~$21.2M) filed an S-1 for a best-efforts offering of up to 20M shares at $1.25/share plus 70M warrants in four tranches (Tranche A–D with exercise prices $1.25–$2.50) and pre-funded warrants, targeting ~$25M gross proceeds (~$23M net). No minimum offering; closing expected ~1 trading day after pricing. Placement agent Maxim Group receives 7% cash fee + 5% warrant coverage. Offering terminates Nov 2026 unless earlier closed.

INNIO reported Q3 2026 revenue of $1.2B (+57% YoY), net income $109.2M (+176%), and Adjusted EBITDA $245.4M (+70%). Equipment Order Backlog reached record $8.0B (+142% YoY) with $2.2B equipment order intake. The company raised FY2026 guidance: total revenue to $3.9–$4.0B (from $3.8–$3.9B) and Adjusted EBITDA to $780–$800M (from $720–$740M). Key orders include 620 MW follow-on, 450 MW Liberty Energy data center order, and Aggreko partnership extended through 2031 with minimum 450 MW commitment.

Philippe E. Mulacek (CIO), Mason H.W. Matschke (CPO), and Sterling A. Mulacek (CAO) of E2 Investment Advisors, LLC collectively own 14,913,913 Empire Petroleum shares. Mulacek and Matschke have engaged in Section 16 transactions within the past 60 days; Sterling has not. This is an amended Schedule 13D disclosure of beneficial ownership by these three officers/directors.

Director Manieu Alexandre Weinstein (PLUR) bought 1.7M shares (~$1.3M) on the open market (67% of holdings). Open-market insider purchase — historically a bullish signal.

CenterPoint Energy raised 2026 non-GAAP EPS guidance to $1.90–$1.92 (9% growth vs. 2025) and initiated 2027 guidance of $2.07–$2.09 (9% growth), extending 7–9% annual growth through 2030. The company increased its 10-year capital plan by $4.0 billion to $70.7 billion and accelerated $1.5 billion into 2026–2030 to support 14% rate-base CAGR, driven by Greater Houston industrial load growth (~12 GW by 2030). On October 1, 2026, it completed the sale of its Ohio natural gas LDC business for ~$2.4 billion net proceeds and a $1.4 billion seller's note at 6.5% interest; the company plans to issue ~$4 billion equity through 2030 and maintain FFO/Debt target of 14–15% through 2030.

HERC reported Q3 2026 equipment rental revenue of $1,254M (+12% YoY) on average fleet growth of only 1.7%, driving dollar utilization up 360 bps to 43.5%. Adjusted EBITDA increased 9% to $603M ($3.91 EPS). The company raised full-year 2026 guidance: equipment rental revenue to $4.475–$4.550B (prior $4.375–$4.475B), adjusted EBITDA to $2.10–$2.15B (prior $2.05–$2.125B), and net capex to $1.0–$1.1B (prior $0.85–$0.95B), citing accelerating mega-project pipeline and H&E acquisition synergies.

Armstrong World Industries reported Q3 2026 net sales of $475.8M (+11.9% YoY), operating income of $131.2M (+11.9%), and adjusted EBITDA of $164M (+11.0%), with adjusted diluted EPS of $2.26 (+10.2%). The company raised full-year 2026 guidance: net sales $1,788–$1,803M (10–11% growth), adjusted EBITDA $602–$612M (8–10% growth), and adjusted diluted EPS $8.30–$8.40 (12–13% growth). Strong performance in Architectural Specialties (+21.5% sales, +33.7% operating income) was driven by organic growth and recent acquisitions (Eventscape, Parallel, Geometrik), while Mineral Fiber grew modestly (+6.6% sales) on favorable AUV and modest volumes, tempered by input cost inflation. Share repurchases totaled 0.4M shares for $75M in Q3; $1.1B remains authorized through Dec 2029.

Nova Minerals Corp announced final permit approval from Alaska Department of Natural Resources for its three-stage antimony project (mining at Styx/Stibium, processing at Whiskey Bravo, refining at Port Mackenzie). The $43.4M Department of War-funded Phase 1 is now fully permitted with engineering complete, equipment delivered, and production targeted for 2027. This clears the regulatory pathway for construction of a domestic U.S. antimony supply chain.